A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses.

2611Background: Tumor-specific neoantigens provide individualized targets for immunotherapy. In silico selection methods are sub-optimal at predicting immunogenic targets, missing up to 70% of true...